Company Monitoring Page for Lundbeck

latest headlines for company on cafepharma

FDA accepts Otsuka, Lundbeck filing for long-acting schizophrenia drug, teeing up April decision date
Fierce Pharma
Tue, 09/13/22 - 10:50 am
Tags:
Otsuka, Lundbeck, schizophrenia, FDA, bipolar disorder, Abilify Maintena
Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled
Fierce Pharma
Thu, 08/18/22 - 12:32 pm
Tags:
Lundbeck, earnings, migraines, CGRPs, Vyepti
Tracking mental health: Lundbeck partnership debuts US mapping dashboard tool
Endpoints
Sun, 02/20/22 - 11:51 am
Tags:
Lundbeck, mental health, COVID-19
Amid crowded migraine market, Lundbeck goes its own way
Pharmaforum
Mon, 11/15/21 - 10:42 am
Tags:
Lundbeck, migraines, Lu AG09222
Citing migraine drug growth and pandemic, Lundbeck to cut 300 jobs and close India facility
Endpoints
Fri, 11/12/21 - 10:39 am
Tags:
Lundbeck, R&D, layoffs, Vyepti, migraines, India
Lundbeck taps Inscopix’ brain-mapping camera tech for CNS research
Pharmaforum
Mon, 09/20/21 - 10:59 pm
Tags:
Lundbeck, Inscopix, CNS, R&D
Lundbeck sells off flopped Alzheimer's drug as Aduhelm approval ups interest
Fierce Biotech
Fri, 07/2/21 - 11:05 am
Tags:
Lundbeck, Denovo Biopharma, Alzheimer's disease
2021 Best Places to Work in Medical Sales
MedReps.com
Tue, 12/22/20 - 10:58 am
Tags:
devices, drug reps, Syneos Health, Teleflex, Avion Pharmaceuticals, Acella, Conmed, Acumed, Lundbeck, Amgen, Biogen, Spark Therapeutics
Lundbeck tops Q3 expectations following strong sales of mental health drugs
Pharmaforum
Tue, 11/3/20 - 10:47 am
Tags:
Lundbeck, earnings
Lundbeck gets cold feet, axes schizophrenia drug trial
Pharmaforum
Thu, 08/6/20 - 11:03 pm
Tags:
Lundbeck, schizophrenia, clinical trials, Lu AF11167
Lilly touts Emgality's ability to reduce migraine patients' overall pain in first look at 'holistic approach'
Fierce Pharma
Wed, 06/17/20 - 09:52 pm
Tags:
Eli Lilly, migraines, Amgen, Teva Pharmaceutical, Lundbeck, Emgality
Lundbeck plotting up to 160 R&D job cuts as it rebuilds pipeline
Fierce Biotech
Tue, 06/9/20 - 12:22 pm
Tags:
Lundbeck, R&D, layoffs
Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward
Endpoints
Fri, 05/8/20 - 10:34 am
Tags:
Ovid Therapeutics, Takeda, Lundbeck, Fragile X syndrome, clinical trials
Lundbeck adds a Parkinson's flop to its list of setbacks, writing off a $1.1 billion deal on mid-stage failure
Endpoints
Mon, 03/30/20 - 10:47 am
Tags:
Lundbeck, R&D, Parkinson's Disease, foliglurax
The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B
Endpoints
Sat, 02/22/20 - 11:29 pm
Tags:
Lundbeck, eptinezumab, migraines, CGRPs, Vyepti
Go or no go? Esperion's double whammy and a look to priority reviews
EP Vantage
Thu, 01/30/20 - 10:43 am
Tags:
FDA, Esperion Therapeutics, Acacia Pharma, Blueprint Medicines, Agile Therapeutics, Lundbeck, Sun Pharma, Biohaven, Durect Corporation
Lundbeck’s digital strategy and how they manage global and local content
Pharmaforum
Tue, 10/15/19 - 10:20 am
Tags:
Lundbeck, digital strategy, digital pharma, digital marketing
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
EP Vantage
Tue, 10/8/19 - 10:53 am
Tags:
M&A, Lundbeck, Alder Biopharmaceuticals, Gilead Sciences, Galapagos, Vertex Pharmaceuticals, Semma, Swedish Orphan Biovitrum, Dova Pharmaceuticals, Novartis, IFM
Alder's migraine drug attracted plenty of dealmakers. The company, not so much
Biopharma Dive
Wed, 09/25/19 - 09:17 am
Tags:
Alder Biopharmaceuticals, M&A, Lundbeck
Alder won’t solve Lundbeck’s headaches
EP Vantage
Mon, 09/16/19 - 05:12 pm
Tags:
Lundbeck, M&A, Alder Biopharmaceuticals, migraines

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.